Back to the list of articles


Trněný Marek

prof. MUDr., CSc.
Born June 22, 1960

  • Hematology-oncology
  • Lymphoma biology, clinical research - targeted therapy and immunotherapy

Education and professional preparation

  • 1979 high school graduation exam in Antonin Dvorak’s Gymnasium Kralupy nad Vltavou
  • 1985 Medicinae Universum Doctor (MUDr.) Faculty of General Medicine, Charles University, Prague, Cum Laudae
  • 1988 board examination 1st grade – internal medicine
  • 1993 board examination 2nd grade – internal medicine
  • 1997 board examination – hematology and transfusion medicine
  • 2007 board examination – medical oncology
  • 2001 scientific degree – CSc.

Employment and academic positions

1994- yet Head, Stem Cell Transplant Program – 1st Fac Med, Charles Univ General Hospital

2003-yet Head, Lymphoma and Chronic Lymphocytic Leukemia program,

– 1st Fac Medicine, Charles University, General Hospital

2008 - yet chair of 1st Dept Medicine 1st Faculty of Medicine,

Charles University, General Hospital - Hematology

2009-2013 Institute of Hematology and Blood Transfusion – Director

2003-yet Chair - Czech Lymphoma Study Group

2022-yet Deputy Chair – Czech Society of Hematology

2005 Associate professor – Internal Medicine – 1st Faculty of Medicine, Charles University

2009 Professor of clinical Oncology – 1st Faculty of Medicine, Charles University

Membership and positions in international organizations and societies

  • European Blood and Marrow Transplantation Society (EBMT)
    2006-2017 chair of Hodgkin´s Lymphoma subcommittee of Lymphoma Working Party
  • European Hematology Association (EHA)
    2008-2009 Scientific advisory board member of Annual Meetings
    Coauthor of EHA Roadmap of European Hematology research
  • American Society of Hematology (ASH)
  • American Society of Clinical Oncology  (ASCO)
    Central and Eastern Europe Regional Council member
  • European Lymphoma Institute – Board of directors,  member
  • Lymphoma Hub – Steering Committee, member
  • European Mantle Cell Lymphoma Network
  • European Society of Medical Oncology (ESMO)
    Member of hematology- oncology guidelines  committee 
  • Scientific board of International Conference on Malignant Lymphoma – faculty member

Membership and positions in Czech organizations Societies and Scientific boards:

  • Czech Society of Hematology – board member in years 1994-2018, 2022 – yet – deputy chair
  • Czech Society of Oncology, Czech Society of internal Medicine
  • Czech Lymphoma Study Group (CLSG) founding Member and Chairman since 2004
  • Scientific board of 1st Faculty of Medicine Charles University
  • Scientific board of Neuron charity


More than 250 papers (indexed in PubMed), H index 53, 15 870 times cited without self-citations (WOS). 

10 selected papers of last 7 years:

  • Trněný M & Lamy T, Walewski J, et al: Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016 Mar;17(3):319-331.
  • Trnĕný M & Verhoef G, Dyer MJ, et al: A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.  Haematologica. 2018 Aug;103(8):1351-1358.
  • Sarkozy C  &  Trneny M &  Xerri L, et al: Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.  J Clin Oncol. 2016 Aug 1;34(22):2575-82
  • Vitolo U & Trněný M & Belada D, et al: Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529-3537.
  • Leonard JP & Trneny M & Izutsu K, et al: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 May 10;37(14):1188-1199.
  • Klanova M, Sehn LH, Bence-Bruckler I, .... & Trneny M.: Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019 Feb 28;133(9):919-926.
  • Klener P, Salek D, Pytlik R, … & Trneny M.: Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol. 2019 Feb;94(2):E50-E53.
  • Kostakoglu L, Martelli M, … & Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021 Mar 9;5(5):1283-1290.
  • Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M et al: Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Jan 27;386(4):351-363.
  • Trněný M & Avigdor A, McKinney MS, et al. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.  EClinicalMedicine. 2023 Aug 18;63:102130.